Vaxcyte, Inc. (PCVX) intrinsic value & 10-year financials
Vaxcyte, Inc. (PCVX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $63.62
- Market cap
- $8.7B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -33.9%
- Free cash flow (FY2025)
- -$669.3M
PCVX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$766.6M | -$5.63 | -$669.3M | — | -33.0% |
| FY2024 | — | -$463.9M | -$3.80 | -$475.1M | — | -29.6% |
| FY2023 | — | -$402.3M | -$4.14 | -$312.9M | — | -94.0% |
| FY2022 | — | -$223.5M | -$3.44 | -$176.4M | — | -125.0% |
| FY2021 | — | -$100.1M | -$1.93 | -$127.9M | — | -44.2% |
| FY2020 | — | -$89.2M | -$3.02 | -$47.8M | — | -74.5% |
| FY2019 | — | -$50.3M | — | -$48.3M | — | 61.3% |
| FY2018 | — | -$29.5M | — | -$32.2M | — | 67.9% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Vaxcyte, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Vaxcyte, Inc. has historically struggled to out-earn its cost of capital, averaging just -33.9% ROIC.
Vaxcyte, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Vaxcyte, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.